Antiproteases in preventing post-ERCP acute pancreatitis

Journal of the Pancreas

Volumn 8, Issue 4, 2007, Pages 509-517

  Tsujino, Takeshi ^a   Kawabe, Takao ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Acute necrotizing; Gabexate; Pancreatitis; Urinastatin

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ANTIBIOTIC AGENT; APROTININ; BETA CAROTENE; BOTULINUM TOXIN A; CORTICOSTEROID; DICLOFENAC; GABEXATE MESILATE; GLYCERYL TRINITRATE; HEPARIN; INTERLEUKIN 10; LIDOCAINE; NIFEDIPINE; OCTREOTIDE; PLACEBO; PROTEINASE INHIBITOR; SOMATOSTATIN; TRYPSIN; TRYPSINOGEN; ULINASTATIN;

ACINAR CELL; ACUTE PANCREATITIS; AMYLASE BLOOD LEVEL; BOLUS INJECTION; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG SAFETY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HUMAN; LONG TERM CARE; MULTIVARIATE ANALYSIS; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VATER PAPILLA STENOSIS;

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; GABEXATE; GLYCOPROTEINS; HUMANS; PANCREATITIS; RANDOMIZED CONTROLLED TRIALS; SERINE PROTEINASE INHIBITORS;

EID: 34547957661     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (58)

1. Cotton PB, Lehman G, Vennes J, Geenen JE, Russel RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383-91.
2. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909-18.
3. Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96:417-23.
4. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54:425-34.
5. Cheng CL, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J, et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006; 101:139-47.
6. Sherman S, Lehman GA. ERCP- and endoscopic sphincterotomy-induced pancreatitis. Pancreas 1991; 6:350-67.
7. Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP. J Pancreas (Online) 2002; 3:162-8.
8. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004; 59:845-64.
9. Brust R, Thomson AB, Wensel RH, Sherbaniuk RW, Costopoulos L. Pancreatic injury following ERCP. Failure of prophylactic benefit of Trasylol. Gastrointest Endosc 1977; 24:77-9.
10. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy. Italian Group. N Engl J Med 1996; 335:919-23.
11. Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56:488-95.
12. Andriulli A, Solmi L, Loperfido S, Leo P, Festa V, Belmonte A, et al. Prophylaxis of ERCP-related pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004; 2:713-8.
13. Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, et al. Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005; 3:376-83.
14. Hajiro K, Tsujimura D, Inoue R, Yamamoto H, Yamamoto T. Effect of FOY on hyperamylasemia after endoscopic retrograde cholangiopancreatography. Gendai Iryo 1978; 10:1375-9.
15. Shimizu Y, Takahashi H, Deura M. Prophylactic effects of preoperative administration of gabexate mesilate (FOY) on post-ERCP pancreatitis. Gendai Iryo 1979; 11:540-4.
16. Pasricha P. Prevention of ERCP-induced pancreatitis: success at last. Gastroenterology 1997; 112:1415-7.
17. Freeman ML, Nelson DB, Sherman S, Haber GB, Fennerty MB, DiSario JA, et al. Same-day discharge after endoscopic biliary sphincterotomy: observations from a prospective multicenter complication study. The Multicenter Endoscopic Sphincterotomy (MESH) Study Group. Gastrointest Endosc 1999; 49:580-6.
18. Tham TC, Vandervoort J, Wong RC, Lichtenstein DR, Van Dam J, Ruymann F, et al. Therapeutic ERCP in outpatients. Gastrointest Endosc 1997; 45:225-30.
19. Mehta SN, Pavone E, Barkun AN. Outpatient therapeutic ERCP: a series of 262 consecutive cases. Gastrointest Endosc 1996; 44:443-9.
20. Hui CK, Lai KC, Wong WM, Yuen MF, Ng M, Chan CK, et al. Outpatients undergoing therapeutic endoscopic retrograde cholangiopancreatography: six-hour versus overnight observation. J Gastroenterol Hepatol 2004; 19:1163-8.
21. Masci E, Cavallini G, Mariani A, Frulloni L, Testoni PA, Curioni S, et al. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis. Am J Gastroenterol 2003; 98:2182-6.
22. Andriulli A, Leandro G, Niro G, Mangia A, Festa V, Gambassi G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51:1-7.
23. Andriulli A, Leandro G, Federici T, Ippolito A, Forlano R, Iacobellis A, Annese V. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis. Gastrointest Endosc 2007; 65:624-32.
24. Benvenuti S, Zancanella L, Piazzi L, Comberlato M, Chilovi F, Germanà B, et al. Prevention of post-ERCP pancreatitis with somatostatin versus gabexate mesylate: A randomized placebo controlled multicenter study. Dig Liver Dis 2006; 38: S15.
25. Kishida S, Takeyama Y, Ueda T, Toyokawa A, Nishikawa J, Yamamoto M, et al. Clinical effects of ulinastatin on severe acute pancreatitis. Shokakika 1994; 19:424-32.
26. Hara A, Arai J, Matsukawa H, Inoue N, Ogata H, Iwao Y, et al. Combination therapy of continuous arterial infusion of nafamostat mesilate and arterial injection of human urinary trypsin inhibitor (ulinastatin) for severe acute pancreatitis. Therapeutic Research 2002; 23:1265-75.
27. Chen SY, Wang JY. Ulinastatin in the treatment of acute pancreatitis: a multicenter clinical trial. Chin J Dig Dis 2002; 3:70-5.
28. Ohnishi H, Kosuzume H, Ashida H, Kato K, Suzuki Y, Honjo I. Therapeutic effects of human urinary trypsin inhibitor on acute experimental pancreatitis. Folia pharmacol japon 1983; 81:235-44.
29. Ohnishi H, Kosuzume H, Ashida Y, Kato K, Honjo I. Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental acute pancreatitis. Dig Dis Sci 1984; 29:26-32.
30. Ishikawa A, Osada A, Fukao K. Inhibitory mechanism of protease inhibitors on SIRS related enzymes. Prog Med 1996; 16:2161-6.
31. Sugiura Y, Nakajima K, Kawase H, Tsubota K, Fujibayashi T, Goto Y. Evaluation of a large dose intravenous administration of urinastatin. Japanese Journal of Acute Medicine 1988; 12:1153-6.
32. Ohara H, Goto K, Noguchi Y, Shiraki S, Kamiya Y, Nakayama Y, et al. The usefulness of ulinastatin for post-ERCP pancreatitis and hyperpancreatoenzymemia-comparative examination between one-shot injection and drip infusion of ulinastatin. Gastroenterology (Tokyo) 1990; 12:361-8.
33. Testoni PA, Bagnolo F, Andriulli A, Bernasconi G, Crotta S, Lella F, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001; 15:965-72.
34. Deviere J, Le Moine O, Van Laethem JL, Eisendrath P, Ghilain A, Severs N, Cohard M. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120:498-505.
35. Raty S, Sand J, Pulkkinen M, Matikainen M, Nordback I. Post-ERCP pancreatitis: reduction by routine antibiotics. J Gastrointest Surg 2001; 5:339-45.
36. Prat F, Amaris J, Ducot B, Bocquentin M, Fritsch J, Choury AD, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002; 56:202-8.
37. Sherman S, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J, et al. Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study. Gastrointest Endosc 2003; 58:23-9.
38. Murray B, Carter R, Imrie C, Evans S, O'suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003; 124:1786-91.
39. Poon RT, Yeung C, Liu CL, Lam CM, Yuen WK, Lo CM, et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: a randomized controlled trial. Gut 2003; 52:1768-73.
40. Rabenstein T, Fischer B, Wiessner V, Schmidt H, Radespiel-Troger M, Hochberger J, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004; 50:606-13.
41. Lavy A, Karban A, Suissa A, Yassin K, Hermesh I, Ben-Amotz A. Natural beta-carotene for the prevention of post-ERCP pancreatitis. Pancreas 2004; 29:e45-50.
42. Gorelick A, Barnett J, Chey W, Anderson M, Elta G. Botulinum toxin injection after biliary sphincterotomy. Endoscopy 2004; 36:170-3.
43. Schwartz JJ, Lew RJ, Ahmad NA, Shah JN, Ginsberg GG, Kochman ML, et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 2004; 59:179-84.
44. Mosler P, Sherman S, Marks J, Watkins JL, Geenen JE, Jamidar P, et al. Oral allopurinol does not prevent the frequency or the severity of post-ERCP pancreatitis. Gastrointest Endosc 2005; 62:245-50.
45. Milewski J, Rydzewska G, Degowska M. Kierzkiewicz M, Rydzewski A. N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol 2006; 12:3751-5.
46. Kaffes AJ, Bourke MJ, Ding S, Alrubaie A, Kwan V, Williams SJ. A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis. Gastrointest Endosc 2006; 64:351-7.
47. Fujishiro H, Adachi K, Imaoka T, Hashimoto T, Kohge N, Moriyama N, et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol 2006; 21:1065-9.
48. Ueki T, Otani K, Kawamoto K, Shimizu A, Fujimura N, Sakaguchi S, Matsui T. Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial. J Gastroenterol 2007; 42:161-7.
49. Lai KH, Lo GH, Cheng JS, Fu MT, Wang EM, Chan HH, et al. Effect of somatostatin on the sphincter of Oddi in patients with acute non-biliary pancreatitis. Gut 2001; 49:843-6.
50. Binmoeller KF, Dumas R, Harris AG, Delmont JP. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci 1992; 37:773-7.
51. Di Francesco V, Angelini G, Bovo P, Casarini MB, Filippini M, Vaona B, et al. Effect of octreotide on sphincter of Oddi motility in patients with acute recurrent pancreatitis: a manometric study. Dig Dis Sci 1996; 41:2392-6.
52. Di Francesco V, Mariani A, Angelini G, Masci E, Frulloni L, Talamini G, et al. Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility. Dig Dis Sci 2002; 47:741-5.
53. Sato Y, Okamura S, Nakasono M, Aoki R, Nakamoto J, Muguruma N, Ito S. Evaluation of serum amylase and gabexate mesilate with endoscopic papillary balloon dilatation. J Med Invest 2007; 54:65-71.
54. Messmann H, Vogt W, Holstege A, Lock G, Heinisch A, von Furstenberg A, et al. Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut 1997; 40:80-5.
55. Testoni PA, Bagnolo F, Caporuscio S, Lella F. Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis. Am J Gastroenterol 1999; 94:1235-41.
56. Lempinen M, Stenman UH, Halttunen J, Puolakkainen P, Haapiainen R, Kemppainen E. Early sequential changes in serum markers of acute pancreatitis induced by endoscopic retrograde cholangiopancreatography. Pancreatology 2005; 5:157-64.
57. Cavallini G, Tittobello A, Frulloni L, Masci E, Mariani A, Di Francesco V. Reply. Gastroenterology 1997; 112:1416-7.
58. Testoni PA. Facts and fiction in the pharmacologic prevention of post-ERCP pancreatitis: a never-ending story. Gastrointest Endosc 2006; 64:732-4.